. 2019 Jun 12;31(4):179–187. doi: 10.1016/j.jsha.2019.05.006

Table 3.

Effect of BB therapy with regard to NYHA class, 6MWT distance, HR and Borg scale before and after 6MWT.

Group 1		Baseline	End of follow-up	Test value	p	Significance
NYHA class	1	0 (0)	8 (42.1)	35.264	<0.001	HS
	2	0 (0)	10 (52.6)
	3	14 (70.0)	1 (5.3)
	4	6 (30.0)	0 (0)
HR before, bpm	Mean ± SD	94.25 ± 13.31	69.47 ± 6.85	8.981	<0.001	HS
HR before, bpm	Range	80–130	60–80	8.981	<0.001	HS
Borg dyspnea before	Median (IQR)	4 (3–5)	2 (1–2)	3.890	<0.001	HS
Borg dyspnea before	Range	2–7	0–4	3.890	<0.001	HS
Borg fatigue before	Median (IQR)	4 (3–5)	2 (1–2)	3.890^c	<0.001	HS
Borg fatigue before	Range	2–7	0–4	3.890^c	<0.001	HS
6MWT distance, m	Mean ± SD	138.00 ± 66.54	278.95 ± 107.44	7.813^b	<0.001	HS
6MWT distance, m	Range	30–280	80–400	7.813^b	<0.001	HS
Premature termination of 6MWT	Negative	17 (85.0)	19 (100.0)	3.243^a	0.072	NS
Premature termination of 6MWT	Dyspnea	3 (15.0)	0 (0.0)	3.243^a	0.072	NS
HR after, bpm	Mean ± SD	120.50 ± 13.17	93.95 ± 10.35	7.245^b	<0.001	HS
HR after, bpm	Range	100–50	80–120	7.245^b	<0.001	HS
Borg dyspnea after	Median (IQR)	8 (6–8)	4 (4–5)	3.856^c	<0.001	HS
Borg dyspnea after	Range	4–10	3–8	3.856^c	<0.001	HS
Borg fatigue after	Median (IQR)	8 (6–8)	4 (4–5)	3.856^c	<0.001	HS
Borg fatigue after	Range	4–10	3–8	3.856^c	<0.001	HS

Data are presented as n (%), mean ± SD, or range.

6MWT = 6-minute walking test distance; BB = beta-blockers; HR = heart rate; HS = highly significant; IQR = interquartile range; MLWHFQ = Minnesota Living with Heart Failure Questionnaire; NS = non-significant; NYHA = New York Heart Association; S = significant.

Chi-square.

independant t test.

Fisher exact test.